Study Shows Paxlovid Can Safely Be Used to Reduce Risk of Severe COVID in People Who Are Pregnant

Findings from a Johns Hopkins Medicine research study published today in JAMA Network Open provide strong evidence that people who are pregnant and have been infected with SARS-CoV-2 (the virus that causes COVID-19) can safely take the antiviral drug Paxlovid to reduce the possibility of severe disease.

Scientists develop effective intranasal mumps-based COVID-19 vaccine candidate

New research has advanced COVID-19 vaccine work in several ways: using a modified live attenuated mumps virus for delivery, showing that a more stable coronavirus spike protein stimulates a stronger immune response, and suggesting a dose up the nose has an advantage over a shot.

Heart Failure Patients Unvaccinated Against COVID-19 Are Three Times More Likely to Die From It Than Boosted Heart Failure Patients

EMBARGOED UNTIL JUNE 9, 2022, 10AM EST (New York, NY – June 9, 2022) – Heart failure patients who are unvaccinated against SARS-CoV-2, the virus that causes COVID-19, are three times more likely to die if infected with the virus…

Why Breakthrough COVID? Antibodies Fighting Original Virus May Be Weaker Against Omicron

If you’re wondering why after two vaccination doses and a booster shot, you still got sick from the omicron strain of the virus that causes COVID-19, one possible answer may have been found in a recent study by researchers at Johns Hopkins Medicine and the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH).

Hand washing and sanitizing not enough: close that toilet lid after flushing!

Leaving toilet lids open after flushing can disperse contaminated droplets beyond a metre and remain in the air for 30 minutes. This is one of the findings revealed in a global review of the risks of bacterial and viral transmission in public bathrooms, undertaken by the ANU and University of South Australia.

In Covid-19 Vaccinated People, Those with Prior Infection Likely to Have More Antibodies

In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable — that is, remain higher over an extended period of time — in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.

Children, Adults Equally Vulnerable to Coronavirus Infection, But Children Less Likely to Become Sick

New research addresses the misconception that children are less susceptible to infection with the new coronavirus. According to a recent report in JAMA Pediatrics, children and adults have similar risks of becoming infected with SARS-CoV-2, but a much larger proportion of infected children do not show symptoms of COVID-19. When one household member is infected, there is a 52% chance they will transmit it to at least one other person with whom they live.

Monoclonal antibody treatment highly effective at reducing COVID-19 hospitalizations

Researchers published interim results in The New England Journal of Medicine from a Phase 3 study of the COVID-19 monoclonal antibody treatment sotrovimab, sponsored by Vir Biotechnology and GlaxoSmithKline. The study found that compared to the placebo group, COVID-19 patients who received sotrovimab had a significantly reduced risk of hospitalization or death and that the treatment, which was administered by intravenous infusion on an outpatient basis, was safe.

MAIT Cell Activation May Play a Role in Fatal Outcomes Among Severe COVID-19 Cases

Antibodies and T cells play a critical role in protection from viral illness, however the exact role of T cell and antibody responses in SARS-CoV-2 infection is unclear. To better understand the immune abnormalities linked to critical illness and death in COVID-19 patients on ICU, researchers conducted a prospective observational study investigating the association of T cell and antibody responses with fatal outcome in severe COVID-19.

Penn mRNA Researchers Drew Weissman and Katalin Karikó Awarded the 2021 Albany Prize

PHILADELPHIA – For their landmark research that set a foundation for the mRNA SARS-CoV-2 vaccines, Drew Weissman, MD, PhD, the Roberts Family Professor of Vaccine Research, and Katalin Karikó;, PhD, an adjunct professor of Neurosurgery at the Perelman School of Medicine at the University of Pennsylvania and a senior vice president at BioNTech, have been selected to receive the 2021 Albany Prize.

Genomic Surveillance Crucial to Mitigate and Contain COVID-19

Researchers say that genomic surveillance to mitigate and contain COVID-19 is equally crucial to detect variants that are phenotypically or antigenically different well before they spread throughout the U.S. and the rest of the world. Genomic surveillance leverages applications of next-generation sequencing and phylogenetic methods to facilitate greater early anticipation as well as initiation of effective strategies to mitigate and contain outbreaks of SARS-CoV-2 variants and other novel viruses.

Mouse Model of COVID-19–induced Lung Injury May Aid Development of Coronavirus Treatments

Article title: The SARS-CoV-2 spike protein subunit 1 induces COVID-19–like acute lung injury in Κ18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells Authors: Ruben Colunga Biancatelli, Pavel Solopov, Elizabeth R. Sharlow, John S. Lazo, Paul Ellis Marik, John…

Novel Method Predicts if COVID-19 Clinical Trials Will Fail or Succeed

Researchers are the first to model COVID-19 completion versus cessation in clinical trials using machine learning algorithms and ensemble learning. They collected 4,441 COVID-19 trials from ClinicalTrials.gov to build a testbed with 693 dimensional features created to represent each clinical trial. These computational methods can predict whether a COVID-19 clinical trial will be completed or terminated, withdrawn or suspended. Stakeholders can leverage the predictions to plan resources, reduce costs, and minimize the time of the clinical study.

Longest known SARS-CoV-2 infection of nearly 300 days successfully treated with new therapy

An immunocompromised individual with the longest known PCR confirmed case of SARS-CoV-2 infection, lasting more than 290 days, has been successfully treated with two investigational monoclonal antibodies (laboratory engineered antibodies). Clinicians and researchers from the University of Bristol and North Bristol NHS Trust (NBT) worked closely to assess and treat the infection and want to highlight the urgent need for improved access to treatments for such people with persistent SARS-CoV-2 infection.

New analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic

Risk of SARS-CoV-2 infection increased 30 percent for households with a recent birthday in counties with high rates of COVID-19

Findings suggest informal social gatherings such as birthday parties played role in infection spread at the height of the coronavirus pandemic

No birthday-bash infection jumps seen in areas with low rates of COVID-19

Households with children’s birthdays had greater risk of SARS-CoV-2 infection than with adult birthdays

Study Identifies How COVID-19 Linked to Alzheimer’s Disease-like Cognitive Impairment

A new Cleveland Clinic-led study has identified mechanisms by which COVID-19 can lead to Alzheimer’s disease-like dementia. The findings, published in Alzheimer’s Research & Therapy, indicate an overlap between COVID-19 and brain changes common in Alzheimer’s, and may help inform risk management and therapeutic strategies for COVID-19-associated cognitive impairment.

Fadiga, percepção de comprometimento cognitivo e transtornos do humor estão associados à síndrome pós-COVID-19, revela estudo da Mayo Clinic

Pacientes diagnosticados com síndrome pós COVID-19, também conhecida como “PCS”, “síndrome de COVID de longa duração” e “sequelas pós-agudas de SARS COV-2”, apresentam sintomas como transtornos de humor, fadiga e comprometimento cognitivo que podem afetar negativamente o retorno ao trabalho e a retomada de atividades normais.